Sangamo Biosciences reported $-47602000 in Pre-Tax Profit for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acceleron Pharma XLRN:US $ -70.45M 6.94M
Alnylam Pharmaceuticals ALNY:US $ -212.93M 24.6M
Biogen BIIB:US $ 814.2M 255M
Bluebird Bio BLUE:US $ -216.93M 14.49M
Five Prime Therapeutics FPRX:US $ -20.85M 0M
Intercept Pharmaceuticals ICPT:US $ -3.63M 7.46M
IONIS PHARMACEUT IONS:US $ -84M 3M
Johnson & Johnson JNJ:US $ 8058M 282M
Karyopharm Therapeutics KPTI:US $ -51706000 1.74M
Novartis NOVN:VX SF 4544M 120M
Omeros OMER:US $ -22703000 5.89M
Regulus Therapeutics RGLS:US $ -8.63M 2.6M
Sangamo Biosciences SGMO:US $ -47.6M 0.45M
Sarepta Therapeutics SRPT:US $ -47.91M 33.85M
Ultragenyx Pharmaceutical RARE:US $ -72.82M 49.15M